within Pharmacolibrary.Drugs.ATC.L;

model L03AX10
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.3333333333333335e-07,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0012,
    k12             = 0.05,
    k21             = 0.05
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L03AX10</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Immunocyanin is an experimental immunostimulant macromolecule isolated from the hemolymph of the mollusk Helix pomatia, previously investigated for its potential use as an immunomodulator in oncology and infectious disease states. It is not an approved drug for clinical use today.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data available for immunocyanin. Parameters are estimated based on general characteristics of high molecular weight protein drugs administered intravenously to adults.</p><h4>References</h4><ol><li><p>Samant, M, et al., &amp; Paolini, JF (2023). First-in-Human Phase 1 Randomized Trial with the Anti-CD40 Monoclonal Antibody KPL-404: Safety, Tolerability, Receptor Occupancy, and Suppression of T-Cell-Dependent Antibody Response. <i>The Journal of pharmacology and experimental therapeutics</i> 387(3) 306–314. DOI:<a href=\"https://doi.org/10.1124/jpet.123.001771\">10.1124/jpet.123.001771</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37699709/\">https://pubmed.ncbi.nlm.nih.gov/37699709</a></p></li><li><p>Espié, P, et al., &amp; Gergely, P (2020). First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody. <i>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</i> 20(2) 463–473. DOI:<a href=\"https://doi.org/10.1111/ajt.15661\">10.1111/ajt.15661</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31647605/\">https://pubmed.ncbi.nlm.nih.gov/31647605</a></p></li><li><p>Li, X, et al., &amp; Liu, H (2025). Lipid-Rapamycin Nanovaccines Overcome the Antidrug Antibody Barrier in Biologic Therapies. <i>ACS nano</i> 19(4) 4309–4323. DOI:<a href=\"https://doi.org/10.1021/acsnano.4c11928\">10.1021/acsnano.4c11928</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39847793/\">https://pubmed.ncbi.nlm.nih.gov/39847793</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L03AX10;
